construction release_alert

Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.

cancel

A Phase 1 Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer

Clinical Trial Grant

Duke Scholars

Principal Investigator Neal Edward Ready Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

January 13, 2021

End Date

January 13, 2025

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

January 13, 2021

End Date

January 13, 2025